CTOs on the Move

MyFOREST Foods

www.myforestfoods.com

 
When it comes to solving our worlds biggest problems, the answers can often be found in nature. The forest is a great place to begin. A lot goes on—between the dirt and the squirrels, and the mosses and the trees—but, what interests us most is whats happening just beneath the forest floor, where lies a hidden, entangled root system of fungi called mycelium. Weve studied and become inspired by mycelium. Weve learned theres a lot you can do with it—from textiles to building materials to packaging alternatives, even to food! Really tasty food. Guided by the wisdom of the woods, MyForest ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

AIG Investments

AIG Investments is a New York, NY-based company in the Business Services sector.

Distribution America Inc

Distribution America Inc is a Charlotte, NC-based company in the Business Services sector.

RD Image Tech

RD Image Tech is a Lancaster, PA-based company in the Business Services sector.

Tannehill Sporting Clays

Tannehill Sporting Clays is a Woodstock, AL-based company in the Business Services sector.

Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. is a biopharmaceutical company based in Waltham, Massachusetts, founded in 2006. Formerly known as Miragen Therapeutics, the company rebranded in January 2021. Viridian is dedicated to discovering, developing, and commercializing treatments for serious and rare diseases, utilizing its expertise in antibody discovery and protein engineering. The company’s product pipeline includes Veligrotug (VRDN-001), a monoclonal antibody in Phase 3 clinical trials for thyroid eye disease, and VRDN-003, a next-generation IGF-1R monoclonal antibody also in Phase 3 trials for the same condition. Additionally, Viridian is developing a portfolio of engineered anti-FcRn inhibitors, such as VRDN-006 and VRDN-008, aimed at treating various autoimmune diseases. Viridians mission is to deliver transformative therapies for patients with underserved diseases, emphasizing innovation and patient-centricity.